Comparing two different regimens of radiotherapy, combined with durvalumab immunotherapy and chemotherapy, in improving the response of rectal cancer to treatment
- Conditions
- ocally advanced rectal cancerCancerMalignant neoplasm of rectum
- Registration Number
- ISRCTN18138369
- Lead Sponsor
- HS Greater Glasgow and Clyde
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 46
1. Willing and able to provide written informed consent for the trial
2. Willing to comply with scheduled visits, treatment plans and laboratory tests and other trial procedures including a willingness to provide repeated biopsy samples of the tumour via flexible sigmoidoscopy
3. Aged =18 years on the day of signing informed consent
4. Histologically confirmed non-metastatic, locally advanced rectal adenocarcinoma deemed appropriate for radical treatment.
5. Non-metastatic disease confirmed with CT of chest/abdomen and pelvis. Suspicious extramesorectal lymph nodes identified on initial staging investigations are not considered exclusion criteria if the local MDT deem these
resectable at and would treat patients with curative intent.
6.The rectal tumour must have at least one of the following high-risk criteria on MRI scan:
6.1. cT3b+
6.2. EMVI positive
6.3. Primary tumour or morphologically malignant lymph node at 1mm or less from the mesorectal fascia or beyond the mesorectal fascia
6.4. Low rectal tumour and the consensus of the multi-disciplinary meeting is that abdomino-perineal excision would be required for sufficient surgical management
7. ECOG performance status 0-1
8. No contra-indication to treatment with pelvic radiotherapy. For example, no pre-existing condition which would deter radiotherapy such as fistulas, severe ulcerative colitis (particularly subjects currently taking sulphasalazine), Crohn’s disease, prior adhesions.
9. Primary disease which can be encompassed within a radical radiotherapy treatment volume
10. Adequate haematological and biochemical function as indicated below. These measurements should be performed within 7 days prior to randomisation:
10.1. Absolute neutrophil count >1.5 x10??/l
10.2. Platelets =100 x10?/l.
10.3. Haemoglobin =90 g/l. Transfusion is acceptable if necessary to increase haemoglobin levels.
10.4. Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) =1.5 xULN unless the subject is receiving
anticoagulant therapy as long as PT or PTT is within the therapeutic range of intended use of anticoagulants
10.5. Activated Partial Thromboplastin Time (aPTT) =1.5 xULN unless the subject is receiving anticoagulant therapy as long
as PT or PTT is within therapeutic range of intended use of anticoagulants
10.6. Renal Creatinine or measured or calculated creatinine clearance (calculated per institutional standard) =1.5 X upper limit of normal (ULN) OR =660 ml/min for subject with creatinine levels >1.5 x institutional ULN. GFR can also be used in place of creatinine or CrCl.
10.7. Bilirubin <1.5 x upper limit of normal (ULN) except for unconjugated hyperbilirubinemia in patients who have Gilbert’s
syndrome. In this case, direct bilirubin must be =ULN for subjects with total bilirubin levels >1.5 ULN.
10.8. AST and ALT =2.5 xULN.
10.9. Albumin =2.5 g/dl
1. Patients with dihydropyrimidine dehydrogenase (DPD) deficiency (any degree).
2. Unable to have MRI assessment
3. Patient weight less than or equal to 30 kg
4. Previous pelvic radiotherapy
5. Metastatic disease defined by computerized tomography (CT) including resectable metastases
6. Previous treatment with immunotherapy including but not limited to anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA4
agents, interferon or anti-IL2 for the treatment of malignancy
7. Previous treatment with chemotherapy for the treatment of current malignancy or treatment with chemotherapy within the last 5 years for a separate malignancy (unless that malignancy was treated squamous/basal cell skin cancer, treated early stage cervical cancer or treated/biochemically stable, organ confined prostate cancer)
8. History of a separate malignancy in the last 5 years (other than treated squamous/basal cell skin cancer, treated early stage cervical cancer or treated/biochemically stable, organ confined prostate cancer)
9. Pregnant or lactating participants. Participants who are of childbearing potential, or with partners of childbearing potential, must agree to use adequate contraceptive measures for the duration of the study and for 6 months after the completion of study treatment.
10. Major surgery within 28 days prior to trial entry
11. Prolongation of corrected QT (QTc) interval to >470 msec when electrolyte balance is normal
12. Recent occurrence (within 3-6 months) of a major thromboembolic event, such as pulmonary embolism or proximal deep vein thrombosis, unless stable on (2 weeks) therapeutic anticoagulation (aspirin <325 mg daily or low molecular-weight heparin [LMWH]). Subjects with a history of clinically non-significant thromboembolic events, not requiring anticoagulation, are allowed to participate in the study.
13. Active inflammatory bowel disease affecting the colon and rectum based on a previous endoscopy and defined by ongoing drug treatment
14. Has an active autoimmune disease that has required systemic treatment in past 2 years (such as the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., levothyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
15. Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease requiring immunosuppressive treatment
16. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisolone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the trial drug
17. Has a history of (non-infectious) interstitial pneumonia or pneumonitis that required steroids or current pneumonitis.
18. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
19. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
20. Has received a live vaccine within 30 days prior to the first dose of trial drug
21. Any patients receiving treatment with brivudine, sorivudine and analogues or patients who have not stopped these dru
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Proportion of patients achieving a clinical complete response (cCR) or a pathological complete response (pCR) at 6 months, in each arm, treatment would be considered to be effective if >30% of patients exhibit a complete clinical or pathological response at 6 months
- Secondary Outcome Measures
Name Time Method